This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Monday, September 23, 2013
After hepatitis C probe, NH, groups push for better drug diversion prevention, detection
After hepatitis C probe, NH, groups push for better drug diversion prevention, detection
By Associated Press,
Updated: Monday, September 23, 1:30 PM
CONCORD, N.H. — After spending a
year investigating the hepatitis C outbreak at Exeter Hospital, New
Hampshire’s public health department is working with two advocacy groups
to share its recommendations.
Chris Adamski of the state Department of Health and Human
Services said Monday her office is committed to working with all
partners to promote better prevention and detection of drug diversion.
Those partners now include the Maryland-based National Association of
Drug Diversion Investigators and a patient advocacy group called
Hepatitis Outbreaks National Organization for Reform, or HONOReform,
Nebraska.
No comments:
Post a Comment